Purolite and Codexis Announce Collaboration to Develop and Market Immobilized Enzymes for Pharmaceutical Market

BALA CYNWYD, Pa. & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Jul. 15, 2013–
Purolite Corporation and Codexis, Inc. (NASDAQ:CDXS) today announced a
joint collaboration to develop and market immobilized enzymes for the
pharmaceutical industry.

Enzymes are immobilized through binding to inert resins, allowing for
easier separation from a reaction mixture, and immobilization often
allows for the use of these enzymes under different conditions and
re-use at a commercial scale. The collaboration will enable Purolite and
Codexis to develop immobilized transaminase enzymes for use in the
production of pharmaceuticals.

“We have selected Purolite as a partner for immobilization based on
their experience with support resins and their ability to supply those
resins at every scale,” said Dr. Peter Seufer-Wasserthal, Senior Vice
President, Pharmaceuticals at Codexis. “Under this new collaboration
with Purolite, we will be launching a kit of immobilized transaminases
as an extension of our CODEX® Screening Kits. The new immobilized enzyme
kits will allow potential customers to quickly assess ideas for
biocatalytic processes.”

“We are very proud to partner with Codexis,” said Dr. Alessandra Basso,
Business Manager of the LifeTech™ unit at Purolite. “The successful
implementation of these ready-to-use immobilized enzymes for fast
screening processes opens the door to new concepts of drug development,
where scientists who are unfamiliar with biocatalytic processes can
easily apply immobilized enzymes to different screening processes that
can speed up new-molecule and API development.”

About Purolite

Purolite was founded in 1981 and is a leading manufacturer of ion
exchange, catalyst, adsorbent and specialty resins. They have developed
the widest platform of resins for enzyme immobilization as part of the
LifeTech product portfolio. Headquartered in Bala Cynwyd, Pa., the
company has ISO-certified manufacturing facilities in the USA, China,
and Romania and operates dedicated R&D centers in the USA, China,
Romania, Russia, and the UK. Purolite, the only company focused
exclusively on the ion exchange market, has 40 sales offices in more
than 30 countries. For more information, see www.purolite.com.

About Codexis, Inc.

Codexis, Inc. engineers enzymes for pharmaceutical, biofuel and chemical
production. Codexis’ proven technology enables scale-up and
implementation of biocatalytic solutions to meet customer needs for
rapid, cost-effective and sustainable process development – from
research to manufacturing. For more information, see www.codexis.com.

Codexis Forward-Looking Statements

This press release contains forward-looking statements relating to
potential launch of immobilized enzyme kits. You should not place undue
reliance on these forward-looking statements because they involve known
and unknown risks, uncertainties and other factors that are, in some
cases, beyond our control and could materially affect actual results.
Factors that could materially affect actual results include our
dependence on a limited number of products in our pharmaceutical
business; potential adverse affects to our business if our customers’
pharmaceutical products are not received well in the markets; and our
ability to develop and commercialize new products for the pharmaceutical
market. Additional factors that could materially affect actual results
can be found in Codexis’ Quarterly Report on Form 10-Q filed with the
Securities and Exchange Commission on May 9, 2013, including under the
caption “Risk Factors.” Codexis expressly disclaims any intent or
obligation to update these forward-looking statements, except as
required by law.

Source: Codexis, Inc.

Codexis, Inc.
Investors
Paul Cox, 212-362-1200
ir@codexis.com
or
Media
Jemma
Connor, +44 161 359 3255
jemma.connor@notchcommunications.co.uk
or
Purolite
Jacob
Brodie, Vice President, 267-255-4829
jacob.brodie@purolite.com